• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

唐氏综合征的分子和细胞改变:寻找治疗靶点。

Molecular and cellular alterations in Down syndrome: toward the identification of targets for therapeutics.

机构信息

Unité de Biologie Fonctionnelle et Adaptative, Sorbonne Paris Cité, Universite Paris Diderot, EAC4413 CNRS, 75205 Paris Cedex 13, France.

出版信息

Neural Plast. 2012;2012:171639. doi: 10.1155/2012/171639. Epub 2012 Jul 12.

DOI:10.1155/2012/171639
PMID:22848846
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3403492/
Abstract

Down syndrome is a complex disease that has challenged molecular and cellular research for more than 50 years. Understanding the molecular bases of morphological, cellular, and functional alterations resulting from the presence of an additional complete chromosome 21 would aid in targeting specific genes and pathways for rescuing some phenotypes. Recently, progress has been made by characterization of brain alterations in mouse models of Down syndrome. This review will highlight the main molecular and cellular findings recently described for these models, particularly with respect to their relationship to Down syndrome phenotypes.

摘要

唐氏综合征是一种复杂的疾病,已经挑战了分子和细胞研究 50 多年。了解由于额外的完整 21 号染色体的存在而导致的形态、细胞和功能改变的分子基础,将有助于针对特定基因和途径进行靶向治疗,以挽救一些表型。最近,通过对唐氏综合征小鼠模型的大脑改变的特征描述,取得了进展。这篇综述将重点介绍最近为这些模型描述的主要分子和细胞发现,特别是它们与唐氏综合征表型的关系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eedd/3403492/7497ec880566/NP2012-171639.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eedd/3403492/7497ec880566/NP2012-171639.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eedd/3403492/7497ec880566/NP2012-171639.001.jpg

相似文献

1
Molecular and cellular alterations in Down syndrome: toward the identification of targets for therapeutics.唐氏综合征的分子和细胞改变:寻找治疗靶点。
Neural Plast. 2012;2012:171639. doi: 10.1155/2012/171639. Epub 2012 Jul 12.
2
An Integrated Human/Murine Transcriptome and Pathway Approach To Identify Prenatal Treatments For Down Syndrome.一种综合人类/鼠类转录组和途径方法,用于鉴定唐氏综合征的产前治疗方法。
Sci Rep. 2016 Sep 2;6:32353. doi: 10.1038/srep32353.
3
Transcriptome and Proteome Profiling of Neural Induced Pluripotent Stem Cells from Individuals with Down Syndrome Disclose Dynamic Dysregulations of Key Pathways and Cellular Functions.唐氏综合征患者诱导多能干细胞的转录组和蛋白质组谱分析揭示了关键途径和细胞功能的动态失调。
Mol Neurobiol. 2019 Oct;56(10):7113-7127. doi: 10.1007/s12035-019-1585-3. Epub 2019 Apr 13.
4
Translational validity and implications of pharmacotherapies in preclinical models of Down syndrome.唐氏综合征临床前模型中药物治疗的转化有效性及意义。
Prog Brain Res. 2020;251:245-268. doi: 10.1016/bs.pbr.2019.10.001. Epub 2019 Nov 1.
5
Alterations of brain circuits in Down syndrome murine models.唐氏综合征小鼠模型中脑回路的改变。
J Chem Neuroanat. 2011 Dec;42(4):317-26. doi: 10.1016/j.jchemneu.2011.09.002. Epub 2011 Sep 16.
6
Neuropathological verisimilitude in animal models of Alzheimer's disease: key to elucidating neurodegenerative pathways and identifying new targets for drug discovery.阿尔茨海默病动物模型中的神经病理学逼真度:阐明神经退行性变途径及确定药物研发新靶点的关键
Am J Pathol. 2002 Feb;160(2):409-11. doi: 10.1016/S0002-9440(10)64858-4.
7
Molecular and cellular mechanisms elucidating neurocognitive basis of functional impairments associated with intellectual disability in Down syndrome.阐明唐氏综合征相关智力障碍的神经认知功能障碍的分子和细胞机制。
Am J Intellect Dev Disabil. 2010 Mar;115(2):83-112. doi: 10.1352/1944-7558-115.2.83.
8
Developmental defects in trisomy 21 and mouse models.21三体综合征及小鼠模型中的发育缺陷。
ScientificWorldJournal. 2006 Sep 19;6:1945-64. doi: 10.1100/tsw.2006.322.
9
[Comprehensive Analyses of Molecules with Altered Expression in the Brain of a Mouse Model of Down Syndrome for Identification of Pharmacotherapeutic Targets].[唐氏综合征小鼠模型大脑中表达改变分子的综合分析以鉴定药物治疗靶点]
Yakugaku Zasshi. 2017;137(7):807-810. doi: 10.1248/yakushi.16-00236-3.
10
Morphological alterations in the hippocampus of the Ts65Dn mouse model for Down Syndrome correlate with structural plasticity markers.唐氏综合征Ts65Dn小鼠模型海马体的形态学改变与结构可塑性标志物相关。
Histol Histopathol. 2018 Jan;33(1):101-115. doi: 10.14670/HH-11-894. Epub 2017 Apr 4.

引用本文的文献

1
Neurodevelopmental disorders and microcephaly: how apoptosis, the cell cycle, tau and amyloid-β precursor protein APPly.神经发育障碍与小头畸形:细胞凋亡、细胞周期、tau蛋白及淀粉样前体蛋白如何发挥作用。
Front Mol Neurosci. 2023 Sep 22;16:1201723. doi: 10.3389/fnmol.2023.1201723. eCollection 2023.
2
Down Syndrome Altered Cell Composition in Blood, Brain, and Buccal Swab Samples Profiled by DNA-Methylation-Based Cell-Type Deconvolution.基于 DNA 甲基化的细胞类型分解技术对唐氏综合征患者血液、大脑和口腔拭子样本的细胞组成进行分析。
Cells. 2023 Apr 15;12(8):1168. doi: 10.3390/cells12081168.
3
Cell type characterization of spatiotemporal gene co-expression modules in Down syndrome brain.

本文引用的文献

1
DYRK1A: a master regulatory protein controlling brain growth.双特异性酪氨酸磷酸化调节激酶 1A:一种控制大脑生长的主调控蛋白。
Neurobiol Dis. 2012 Apr;46(1):190-203. doi: 10.1016/j.nbd.2012.01.007. Epub 2012 Jan 26.
2
Brain phenotype of transgenic mice overexpressing cystathionine β-synthase.过表达胱硫醚-β-合酶的转基因小鼠的脑表型。
PLoS One. 2012;7(1):e29056. doi: 10.1371/journal.pone.0029056. Epub 2012 Jan 12.
3
Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial.
唐氏综合征大脑中时空基因共表达模块的细胞类型特征分析
iScience. 2022 Dec 28;26(1):105884. doi: 10.1016/j.isci.2022.105884. eCollection 2023 Jan 20.
4
Ten Reasons Why People With Down Syndrome are Protected From the Development of Most Solid Tumors -A Review.唐氏综合征患者免受大多数实体瘤发生影响的十个原因——综述
Front Genet. 2021 Nov 5;12:749480. doi: 10.3389/fgene.2021.749480. eCollection 2021.
5
Down syndrome iPSC model: endothelial perspective on tumor development.唐氏综合征诱导多能干细胞模型:肿瘤发生的内皮细胞视角
Oncotarget. 2020 Sep 8;11(36):3387-3404. doi: 10.18632/oncotarget.27712.
6
Overexpression of the DYRK1A Gene (Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A) Induces Alterations of the Serotoninergic and Dopaminergic Processing in Murine Brain Tissues.DYRK1A 基因(双特异性酪氨酸磷酸化调节激酶 1A)过表达诱导小鼠脑组织中 5-羟色胺能和多巴胺能处理的改变。
Mol Neurobiol. 2018 May;55(5):3822-3831. doi: 10.1007/s12035-017-0591-6. Epub 2017 May 25.
7
Involvement of Potassium and Cation Channels in Hippocampal Abnormalities of Embryonic Ts65Dn and Tc1 Trisomic Mice.钾离子通道和阳离子通道在胚胎 Ts65Dn 和 Tc1 三体小鼠海马异常中的作用。
EBioMedicine. 2015 Jul 31;2(9):1048-62. doi: 10.1016/j.ebiom.2015.07.038. eCollection 2015 Sep.
8
Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome.抑制淀粉样前体蛋白(APP)γ-分泌酶可恢复唐氏综合征Ts65Dn小鼠模型中的音猬因子(Sonic Hedgehog)信号传导和神经发生。
Neurobiol Dis. 2015 Oct;82:385-396. doi: 10.1016/j.nbd.2015.08.001. Epub 2015 Aug 5.
9
Modeling neurodevelopmental disorders using human pluripotent stem cells.利用人类多能干细胞建模神经发育障碍。
Stem Cell Rev Rep. 2014 Aug;10(4):494-511. doi: 10.1007/s12015-014-9507-2.
10
New innovations: therapeutic opportunities for intellectual disabilities.新的创新:智力障碍的治疗机会。
Ann Neurol. 2013 Sep;74(3):382-90. doi: 10.1002/ana.24002.
美金刚治疗 40 岁以上唐氏综合征成人痴呆症(MEADOWS):一项随机、双盲、安慰剂对照试验。
Lancet. 2012 Feb 11;379(9815):528-36. doi: 10.1016/S0140-6736(11)61676-0. Epub 2012 Jan 10.
4
Dyrk1A influences neuronal morphogenesis through regulation of cytoskeletal dynamics in mammalian cortical neurons.Dyrk1A 通过调节哺乳动物皮质神经元中的细胞骨架动力学来影响神经元形态发生。
Cereb Cortex. 2012 Dec;22(12):2867-77. doi: 10.1093/cercor/bhr362. Epub 2012 Jan 2.
5
Environmental enrichment decreases GABAergic inhibition and improves cognitive abilities, synaptic plasticity, and visual functions in a mouse model of Down syndrome.在唐氏综合征小鼠模型中,环境富集可减少γ-氨基丁酸能抑制作用,并改善认知能力、突触可塑性和视觉功能。
Front Cell Neurosci. 2011 Dec 23;5:29. doi: 10.3389/fncel.2011.00029. eCollection 2011.
6
miRNA-155 upregulation and complement factor H deficits in Down's syndrome.唐氏综合征中miRNA - 155上调与补体因子H缺乏
Neuroreport. 2012 Feb 15;23(3):168-73. doi: 10.1097/WNR.0b013e32834f4eb4.
7
Dysfunctional hippocampal inhibition in the Ts65Dn mouse model of Down syndrome.唐氏综合征 Ts65Dn 小鼠模型中海马抑制功能障碍。
Exp Neurol. 2012 Feb;233(2):749-57. doi: 10.1016/j.expneurol.2011.11.033. Epub 2011 Dec 8.
8
Altered expression of neuropeptides in the primary somatosensory cortex of the Down syndrome model Ts65Dn.唐氏综合征模型 Ts65Dn 初级体感皮层中神经肽的表达改变。
Neuropeptides. 2012 Feb;46(1):29-37. doi: 10.1016/j.npep.2011.10.002. Epub 2011 Nov 10.
9
Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome.唐氏综合征 Ts65Dn 小鼠模型中 GABAA 和 GABAB 受体介导的神经递质传递效率增加。
Neurobiol Dis. 2012 Feb;45(2):683-91. doi: 10.1016/j.nbd.2011.10.009. Epub 2011 Oct 17.
10
Chronic Treatment with a Promnesiant GABA-A α5-Selective Inverse Agonist Increases Immediate Early Genes Expression during Memory Processing in Mice and Rectifies Their Expression Levels in a Down Syndrome Mouse Model.用一种促记忆的GABA-A α5选择性反向激动剂进行慢性治疗可增加小鼠记忆处理过程中即早基因的表达,并纠正唐氏综合征小鼠模型中它们的表达水平。
Adv Pharmacol Sci. 2011;2011:153218. doi: 10.1155/2011/153218. Epub 2011 Oct 19.